NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=136058&from=3  CLASS PERIOD: February 3, 2022 ...

Group 1: Nvidia and AI Market - Nvidia's GPU Technology Conference (GTC) is anticipated to provide positive updates on demand and production, potentially attracting investors back to tech stocks [2][3] - The iShares Future AI & Tech ETF (ARTY) has seen a decline of 18% from its recent market high, indicating a bearish trend in the AI sector [3] - BofA analyst Vivek Arya expects updates on Nvidia's pipeline, particularly the Blackwell Ultra and Rubin, and its competitive position in China [4] Group 2: Federal Reserve and Economic Projections - Fed Chairman Jerome Powell is expected to face questions regarding the impact of tariffs on growth and inflation during his upcoming press conference [6][7] - Economists from Wells Fargo predict a modest downgrade to economic projections for 2025, with real GDP growth expected to dip below 2.0% [10] - The latest consumer sentiment report shows a rise in inflation expectations, with year-ahead expectations increasing to 4.9% from 4.3% [8] Group 3: Earnings Reports and Market Sentiment - FedEx is projected to report earnings of $4.67 per share on revenue of $21.91 billion, with expectations of improved efficiency and higher margins in FY26 [11] - Other companies reporting earnings include KE Holdings, XPeng, Tencent Music, and ZTO Express, indicating a busy earnings calendar [11][12] - Bill Gross comments on the current market volatility and the potential impact of tariffs on global economies, suggesting a bearish outlook [15][16]

Core Insights - The global membrane chromatography market is projected to grow from an estimated USD 324.4 million in 2024 to USD 779.3 million by 2030, with a compound annual growth rate (CAGR) of 16.0% from 2025 to 2030 [3][7]. Market Overview - The growth of the membrane chromatography market is primarily driven by the increasing demand for biopharmaceuticals and a heightened regulatory focus on cleaning validation for downstream purification processes [3][4]. - Membrane chromatography offers significant advantages over traditional column chromatography, including higher binding capacities and reduced buffer consumption, which are critical for optimizing biopharmaceutical production [3][4]. Regulatory Environment - Regulatory approvals for biopharmaceutical manufacturing are fueling market growth, as evidenced by Boehringer Ingelheim Biopharmaceuticals China's successful pre-approval inspections by the European Medicines Agency and the U.S. Food and Drug Administration in April 2024 [5]. - The increasing endorsement of biopharmaceuticals by regulatory bodies is driving demand for membrane chromatography [5]. Research and Development - The biopharmaceutical industry's annual R&D spending exceeds USD 202 billion, significantly outpacing other sectors, which underscores the commitment to innovation and the growing number of product launches [6]. - Innovations such as Waters Corporation's introduction of the XBridge Premier GTx BEH SEC columns in August 2023 for gene therapy applications exemplify advancements in membrane chromatography technology [6]. Market Segmentation - The report segments the global membrane chromatography market based on product, technique, end use, and region, providing a comprehensive analysis of trends and forecasts from 2018 to 2030 [2][8]. - Key product segments include capsules, cassettes, cartridges, syringe filters, and membrane filters, among others [8][10]. Competitive Landscape - The competitive landscape includes major players such as 3M, Asahi Kasei, Danaher, Merck, and Thermo Fisher Scientific, highlighting the diverse market participants and their strategic positioning [10][12].

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Merck (MRK) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Merck currently has an average brokerage recommendation (ABR) of 1. ...

NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK).Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/merck-co-inc-loss-submission-form/?id=134604&from=4 CLASS PERIOD: February 3, 2022 to Febr ...

Core Viewpoint - Merck's recent earnings report shows strong performance with adjusted earnings and revenue growth, but challenges in specific product sales, particularly Gardasil in China, may impact future guidance and stock performance [2][3][21]. Financial Performance - Adjusted earnings for Q4 2024 were $1.72 per share, exceeding the Zacks Consensus Estimate of $1.69, and significantly up from $0.03 in the same quarter last year [2]. - Revenues for Q4 2024 rose 7% year over year to $15.62 billion, driven by Keytruda and new products, surpassing the Zacks Consensus Estimate of $15.56 billion [3]. - Full-year 2024 sales increased 7% to $64.2 billion, beating the Zacks Consensus Estimate of $64.06 billion [18]. Segment Performance - The Pharmaceutical segment generated revenues of $14.04 billion, up 7% year over year, driven by oncology and cardiovascular drugs [4]. - Keytruda sales reached $7.84 billion, a 21% increase year over year, benefiting from strong demand in various cancer indications [5]. - The Animal Health segment reported revenues of $1.40 billion, up 9% year over year, driven by higher demand and pricing [14]. Product-Specific Insights - Sales of Gardasil vaccines fell 18% to $1.55 billion due to lower demand in China, leading to a temporary halt in shipments [7][9]. - Januvia/Janumet sales declined 36% year over year to $487 million, impacted by lower demand and pricing in the U.S. [12]. - New drug Winrevair generated $200 million in sales, reflecting strong uptake in the U.S. market [13]. Guidance and Future Outlook - For 2025, Merck expects revenues between $64.1 billion and $65.6 billion, representing 2% to 4% growth, but this guidance is below the Zacks Consensus Estimate of $68.05 billion [20][21]. - The company anticipates a negative impact on sales from the temporary halt of Gardasil shipments in China and foreign exchange fluctuations [21][22]. - Adjusted earnings per share for 2025 are projected to be between $8.88 and $9.03, slightly below the Zacks Consensus Estimate of $9.18 [25]. Market Position and Trends - Merck's stock has seen a 3.9% increase over the past month, outperforming the S&P 500, but recent estimates have trended downward, indicating potential challenges ahead [1][27]. - The company holds a Zacks Rank 4 (Sell), suggesting expectations of below-average returns in the near term [30].

Core Insights - Ascentage Pharma's drug olverembatinib has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration for treating newly-diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with low-intensity chemotherapy [1][2][3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on discovering, developing, and commercializing therapies for unmet medical needs, particularly in hematological malignancies [10][11] - The company is listed on both the Hong Kong Stock Exchange and Nasdaq, indicating its global presence and investment appeal [10] Drug Development and Approval - Olverembatinib is the first third-generation BCR-ABL inhibitor approved in China, with prior approvals for chronic-phase chronic myeloid leukemia (CML-CP) and gastrointestinal stromal tumors [5][12] - The drug has been included in the China National Reimbursement Drug List, enhancing its accessibility to patients [5][12] - A global Phase III study has been cleared for olverembatinib in combination with chemotherapy, positioning it to potentially be the first TKI approved for first-line treatment of Ph+ ALL in China [6] Clinical Significance - The incidence rate of ALL in China is approximately 0.69 per 100,000, with Ph+ ALL representing 20%-30% of adult cases, highlighting a significant unmet medical need [4] - Prior to TKIs, the five-year overall survival rate for Ph+ ALL patients treated with chemotherapy was below 20%, underscoring the importance of new treatment options [4] Regulatory and Market Impact - BTDs are granted to innovative drugs that address serious conditions with no existing treatment, allowing for prioritized development and review processes [3] - The recognition of olverembatinib's clinical value by regulatory authorities is expected to accelerate its development and availability to patients [7]

Core Viewpoint - AbbVie is expanding its presence in the obesity treatment market by in-licensing GUB014295, a long-acting amylin analog, from Gubra, with a total potential deal value of $2.225 billion [1][2][3] Industry Overview - The obesity market is projected to reach $100 billion by 2030, with current dominance by GLP-1 drugs from Eli Lilly and Novo Nordisk [3] - Major pharmaceutical companies, including Merck, Pfizer, Amgen, and AstraZeneca, are actively pursuing opportunities in the obesity space through in-house development or licensing deals [3] AbbVie's Product Performance - AbbVie has successfully launched Skyrizi and Rinvoq, generating combined sales of $17.7 billion in 2024, particularly excelling in the inflammatory bowel disease market [5][6] - The company anticipates combined sales of Skyrizi and Rinvoq to exceed $31 billion by 2027, driven by market growth and new indications [7] Pipeline and Acquisitions - AbbVie has a robust pipeline with several early/mid-stage candidates and expects multiple regulatory submissions and approvals in the next 12 months [8][9] - The company has been active in acquisitions, signing over 20 early-stage deals in 2024 to enhance its pipeline in immunology, oncology, and neuroscience [11][12] Sales Trends and Challenges - AbbVie is experiencing declining sales from Humira due to biosimilar competition, with a sharper decline expected in 2025 [13] - The aesthetics portfolio, including Juvederm fillers, has also seen a decline, with a 14.6% drop in sales in 2024 [14][15] Stock Performance and Valuation - AbbVie stock has outperformed the industry with a 14.8% increase over the past year [16][18] - The stock trades at a price/earnings ratio of 16.52, slightly below the industry average of 17.80, but higher than many large drugmakers [19][20] Earnings Estimates - The Zacks Consensus Estimate for AbbVie's 2025 earnings has increased from $12.24 to $12.29 per share, indicating positive sentiment [22]

Merck (MRK) ended the recent trading session at $92.25, demonstrating a +1.84% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 1.59%. Elsewhere, the Dow gained 1.39%, while the tech-heavy Nasdaq added 1.63%.Prior to today's trading, shares of the pharmaceutical company had lost 8.46% over the past month. This has lagged the Medical sector's loss of 0.63% and the S&P 500's loss of 2.42% in that time.Market participants will be closely following the f ...

Merck (MRK) stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and provided a disappointing guidance for 2025.On Feb. 4, Merck announced its fourth-quarter and full-year 2024 results. While the drug giant beat estimates for both earnings and sales, its financial outlook for 2025, provided along with the earnings release, fell short of investor expectations.Sales of human papillomavirus vaccine, Gardasil, which is Merck’s second largest product, dec ...